Genmab details ovarian cancer data; Lilly's Jaypirca gets a label expansion

Data ReadoutpositiveRina-SJaypircaPositive

AI Analysis

Summary

Genmab reported positive clinical data for Rina-S, an FRα-directed ADC, achieving 45.9% objective response rate in platinum-resistant ovarian cancer patients. Eli Lilly's Jaypirca received a label expansion.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Rina-S achieved 45.9% objective response rate in platinum-resistant ovarian cancer patients

Importance:6/10

Sentiment:

0.70

oncologyADCovarian cancerclinical datalabel expansion

Related Companies

$GMAB $LLY $BIIB

Read the original article

Published by Endpoints News on October 5, 2026 3:02 PM

Read Original